JP2007505877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505877A5 JP2007505877A5 JP2006526691A JP2006526691A JP2007505877A5 JP 2007505877 A5 JP2007505877 A5 JP 2007505877A5 JP 2006526691 A JP2006526691 A JP 2006526691A JP 2006526691 A JP2006526691 A JP 2006526691A JP 2007505877 A5 JP2007505877 A5 JP 2007505877A5
- Authority
- JP
- Japan
- Prior art keywords
- urea
- benzyl
- trifluoromethyl
- alkyl
- indazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 150000001204 N-oxides Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005059 halophenyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- ZKHZJGDJWVTEDF-UHFFFAOYSA-N 1-(1,2-benzothiazol-5-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=C(SN=C2)C2=C1 ZKHZJGDJWVTEDF-UHFFFAOYSA-N 0.000 claims 1
- MIWVXXPEKGDYBA-UHFFFAOYSA-N 1-(1,2-benzothiazol-7-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CC2=C1SN=C2 MIWVXXPEKGDYBA-UHFFFAOYSA-N 0.000 claims 1
- FXFDPRICOKENNR-UHFFFAOYSA-N 1-(1,3-benzothiazol-5-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=C(SC=N2)C2=C1 FXFDPRICOKENNR-UHFFFAOYSA-N 0.000 claims 1
- GWZIRRZEGZMKCL-UHFFFAOYSA-N 1-(1,3-benzothiazol-6-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=C(N=CS2)C2=C1 GWZIRRZEGZMKCL-UHFFFAOYSA-N 0.000 claims 1
- VWTCLFQQYGVGNJ-UHFFFAOYSA-N 1-(1,3-benzothiazol-7-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CC2=C1SC=N2 VWTCLFQQYGVGNJ-UHFFFAOYSA-N 0.000 claims 1
- UYFJNTVXZQWDTQ-UHFFFAOYSA-N 1-(1-methyl-2-oxo-3h-indol-4-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound CN1C(=O)CC2=C1C=CC=C2NC(=O)NCC1=CC=C(C(F)(F)F)C=C1 UYFJNTVXZQWDTQ-UHFFFAOYSA-N 0.000 claims 1
- RJWWWCFBFUBOEB-UHFFFAOYSA-N 1-(1-methylindazol-4-yl)-3-[[4-(trifluoromethoxy)phenyl]methyl]urea Chemical compound C1=CC=C2N(C)N=CC2=C1NC(=O)NCC1=CC=C(OC(F)(F)F)C=C1 RJWWWCFBFUBOEB-UHFFFAOYSA-N 0.000 claims 1
- CFGGYUAMWOASFU-UHFFFAOYSA-N 1-(1-methylindazol-4-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC=C2N(C)N=CC2=C1NC(=O)NCC1=CC=C(C(F)(F)F)C=C1 CFGGYUAMWOASFU-UHFFFAOYSA-N 0.000 claims 1
- DTVUVWWLSNDWLJ-UHFFFAOYSA-N 1-(1h-benzimidazol-4-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CC2=C1N=CN2 DTVUVWWLSNDWLJ-UHFFFAOYSA-N 0.000 claims 1
- DJTQGUFXNJDXRL-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[[4-(trifluoromethoxy)phenyl]methyl]urea Chemical compound C1=CC(OC(F)(F)F)=CC=C1CNC(=O)NC1=CC=CC2=C1C=NN2 DJTQGUFXNJDXRL-UHFFFAOYSA-N 0.000 claims 1
- MMDHAGYNJNCDAF-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CC2=C1C=NN2 MMDHAGYNJNCDAF-UHFFFAOYSA-N 0.000 claims 1
- BCJWPBONPCHUCK-UHFFFAOYSA-N 1-(1h-indazol-5-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=C(NN=C2)C2=C1 BCJWPBONPCHUCK-UHFFFAOYSA-N 0.000 claims 1
- GZNMGIKMOUGAQS-UHFFFAOYSA-N 1-(1h-indazol-6-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=C(C=NN2)C2=C1 GZNMGIKMOUGAQS-UHFFFAOYSA-N 0.000 claims 1
- DIZORDSNHUYNCI-UHFFFAOYSA-N 1-(1h-indol-4-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CC2=C1C=CN2 DIZORDSNHUYNCI-UHFFFAOYSA-N 0.000 claims 1
- IOSPLGKBWAXALM-UHFFFAOYSA-N 1-(1h-indol-5-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=C(NC=C2)C2=C1 IOSPLGKBWAXALM-UHFFFAOYSA-N 0.000 claims 1
- WINLWNYSQIMVGM-UHFFFAOYSA-N 1-(2,3-dihydro-1-benzofuran-4-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CC2=C1CCO2 WINLWNYSQIMVGM-UHFFFAOYSA-N 0.000 claims 1
- BGBCEEDDPITDGW-UHFFFAOYSA-N 1-(2-methyl-1,3-benzothiazol-5-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(=O)NCC1=CC=C(C(F)(F)F)C=C1 BGBCEEDDPITDGW-UHFFFAOYSA-N 0.000 claims 1
- SKHLZELKYZFSHO-UHFFFAOYSA-N 1-(2-methyl-1,3-benzoxazol-5-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C=1C=C2OC(C)=NC2=CC=1NC(=O)NCC1=CC=C(C(F)(F)F)C=C1 SKHLZELKYZFSHO-UHFFFAOYSA-N 0.000 claims 1
- GJPALMHDYAOBRM-UHFFFAOYSA-N 1-(2-methyl-1,3-benzoxazol-7-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C=12OC(C)=NC2=CC=CC=1NC(=O)NCC1=CC=C(C(F)(F)F)C=C1 GJPALMHDYAOBRM-UHFFFAOYSA-N 0.000 claims 1
- YTLIVSBWOLDSTF-UHFFFAOYSA-N 1-(2-methylindazol-4-yl)-3-[[4-(trifluoromethoxy)phenyl]methyl]urea Chemical compound C=1C=CC2=NN(C)C=C2C=1NC(=O)NCC1=CC=C(OC(F)(F)F)C=C1 YTLIVSBWOLDSTF-UHFFFAOYSA-N 0.000 claims 1
- MMLOGZYVHBSNCW-UHFFFAOYSA-N 1-(2-oxo-1,3-dihydroindol-4-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CC2=C1CC(=O)N2 MMLOGZYVHBSNCW-UHFFFAOYSA-N 0.000 claims 1
- AMXZKXUOBCCOFN-UHFFFAOYSA-N 1-(3-methyl-2h-indazol-4-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C=12C(C)=NNC2=CC=CC=1NC(=O)NCC1=CC=C(C(F)(F)F)C=C1 AMXZKXUOBCCOFN-UHFFFAOYSA-N 0.000 claims 1
- AIPSQHDGMAAIJT-UHFFFAOYSA-N 1-(4-chloro-1,2-benzothiazol-7-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=C(Cl)C2=C1SN=C2 AIPSQHDGMAAIJT-UHFFFAOYSA-N 0.000 claims 1
- XCGMGBBVHOJQRA-UHFFFAOYSA-N 1-(4h-imidazo[1,2-a]indol-5-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CC2=C1CC1=NC=CN21 XCGMGBBVHOJQRA-UHFFFAOYSA-N 0.000 claims 1
- RJIBXKJKRRRUGA-UHFFFAOYSA-N 1-(5-fluoro-1h-indazol-4-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound FC1=CC=C2NN=CC2=C1NC(=O)NCC1=CC=C(C(F)(F)F)C=C1 RJIBXKJKRRRUGA-UHFFFAOYSA-N 0.000 claims 1
- VSLKBALQNGPKGC-UHFFFAOYSA-N 1-(6-fluoro-1-methylindazol-4-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=C(F)C=C2N(C)N=CC2=C1NC(=O)NCC1=CC=C(C(F)(F)F)C=C1 VSLKBALQNGPKGC-UHFFFAOYSA-N 0.000 claims 1
- SMIDUPZPRWZJRE-UHFFFAOYSA-N 1-(6-fluoro-1h-indazol-4-yl)-3-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C=12C=NNC2=CC(F)=CC=1NC(=O)NCC1=CC=C(C(F)(F)F)C=C1F SMIDUPZPRWZJRE-UHFFFAOYSA-N 0.000 claims 1
- PDTNMCHJOHAQKV-UHFFFAOYSA-N 1-(6-fluoro-1h-indazol-4-yl)-3-[[4-(trifluoromethoxy)phenyl]methyl]urea Chemical compound C=12C=NNC2=CC(F)=CC=1NC(=O)NCC1=CC=C(OC(F)(F)F)C=C1 PDTNMCHJOHAQKV-UHFFFAOYSA-N 0.000 claims 1
- IHTTZJGIEQLKSD-UHFFFAOYSA-N 1-(6-fluoro-1h-indazol-4-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C=12C=NNC2=CC(F)=CC=1NC(=O)NCC1=CC=C(C(F)(F)F)C=C1 IHTTZJGIEQLKSD-UHFFFAOYSA-N 0.000 claims 1
- WFBXIGJUMYSJIG-UHFFFAOYSA-N 1-(7-amino-1,2-benzothiazol-4-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=2C=NSC=2C(N)=CC=C1NC(=O)NCC1=CC=C(C(F)(F)F)C=C1 WFBXIGJUMYSJIG-UHFFFAOYSA-N 0.000 claims 1
- MKVVWGHDVFQXJI-UHFFFAOYSA-N 1-(triazolo[1,5-a]pyridin-4-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CN2C1=CN=N2 MKVVWGHDVFQXJI-UHFFFAOYSA-N 0.000 claims 1
- RUDQTOXUQFTRGA-UHFFFAOYSA-N 1-(triazolo[1,5-a]pyridin-7-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CC2=CN=NN12 RUDQTOXUQFTRGA-UHFFFAOYSA-N 0.000 claims 1
- LETSCFBFLUPBOV-UHFFFAOYSA-N 1-[1-methyl-6-(trifluoromethyl)indazol-4-yl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=C(C(F)(F)F)C=C2N(C)N=CC2=C1NC(=O)NCC1=CC=C(C(F)(F)F)C=C1 LETSCFBFLUPBOV-UHFFFAOYSA-N 0.000 claims 1
- WHSRYKAYDMTIFW-UHFFFAOYSA-N 1-[6-(trifluoromethyl)-1h-indazol-4-yl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC(C(F)(F)F)=CC2=C1C=NN2 WHSRYKAYDMTIFW-UHFFFAOYSA-N 0.000 claims 1
- OYSDRSMNMVUQNK-UHFFFAOYSA-N 1-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-3-(1h-indazol-4-yl)urea Chemical compound FC1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CC2=C1C=NN2 OYSDRSMNMVUQNK-UHFFFAOYSA-N 0.000 claims 1
- TYTGHPXWAYOTEG-UHFFFAOYSA-N 1-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-3-(1h-indazol-4-yl)urea Chemical compound C1=C(C(F)(F)F)C(F)=CC(CNC(=O)NC=2C=3C=NNC=3C=CC=2)=C1 TYTGHPXWAYOTEG-UHFFFAOYSA-N 0.000 claims 1
- NZFJCKJVSPFQBS-UHFFFAOYSA-N 1-imidazo[1,2-a]pyridin-5-yl-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CC2=NC=CN12 NZFJCKJVSPFQBS-UHFFFAOYSA-N 0.000 claims 1
- FNPGUYUTCVNRGL-UHFFFAOYSA-N 1-imidazo[1,5-a]pyridin-5-yl-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CC2=CN=CN12 FNPGUYUTCVNRGL-UHFFFAOYSA-N 0.000 claims 1
- QCUZNAKLEPBLHQ-UHFFFAOYSA-N 1-imidazo[1,5-a]pyridin-8-yl-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)NC1=CC=CN2C1=CN=C2 QCUZNAKLEPBLHQ-UHFFFAOYSA-N 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (10)
- 式(I):
EはC又はNであり;
5員環内の点線の円は環が不飽和でも部分飽和でもよいことを意味し;
R1はハロゲン、ヒドロキシ、C1−6アルキル、ハロC1−6アルキル、ヒドロキシC1−6アルキル、C1−6アルコキシ、ハロC1−6アルコキシ、ヒドロキシC1−6アルコキシ、C3−7シクロアルキル、C3−5シクロアルキルC1−4アルキル、NR7R8、(NR7R8で置換された)C1−6アルキル、(NR7R8で置換された)C1−6アルコキシ、オキソ、シアノ、SO2NR7R8、CONR7R8、NHCOR9、又はNHSO2R9であり;
R2はハロゲン、ヒドロキシ、C1−6アルキル、ハロC1−6アルキル、ヒドロキシC1−6アルキル、C1−6アルコキシ、ハロC1−6アルコキシ、ヒドロキシC1−6アルコキシ、C3−7シクロアルキル、C3−5シクロアルキルC1−4アルキル、NR7R8、(NR7R8で置換された)C1−6アルキル、(NR7R8で置換された)C1−6アルコキシ、シアノ、SO2NR7R8、CONR7R8、NHCOR9、又はNHSO2R9であり;
R3及びR4は各々独立して水素、C1−6アルキル、フェニル又はハロフェニルであり;
R5及びR6は出現毎に独立して水素、C1−6アルキル、フェニル、ハロフェニル又はカルボキシであり;
R7及びR8は出現毎に独立して水素、C1−6アルキル、C3−7シクロアルキル又はフルオロC1−6アルキルであり;または
R7及びR8はこれらが結合している窒素原子と共に、場合によりヒドロキシ又はC1−4アルコキシから選択される1又は2個の基で置換された4〜7員複素環を形成し、前記環は場合により酸素もしくは硫黄原子、S(O)もしくはS(O)2、又は(NHもしくはNRa部分(式中、Raは場合によりヒドロキシもしくはC1−4アルコキシで置換されたC1−4アルキルであるか、又はRaはCOC1−4アルキルもしくはSO2C1−4アルキルである。)の一部となる)第2の窒素原子を前記環原子の1つとして含んでいてもよく;
R9はC1−6アルキル又はフルオロC1−6アルキルであり;
Xは酸素又は硫黄原子であり;
Yはアリール、ヘテロアリール、カルボシクリル又は融合カルボシクリル基であり;
nは0又は1〜3の整数であり;
pは0又は1〜4の整数であり;
qは0又は1〜3の整数である。]の化合物又は医薬的に許容可能なその塩、N−オキシドもしくはプロドラッグ。 - N−(1H−インダゾール−6−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1,3−ベンゾチアゾール−6−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(2−メチル−1,3−ベンゾチアゾール−5−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1H−インドール−5−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1,3−ベンゾチアゾール−5−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1H−インドール−4−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−イミダゾ[1,5−a]ピリジン−8−イル−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1H−インダゾール−4−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1H−インダゾール−4−イル)−N’−[4−(トリフルオロメトキシ)ベンジル]尿素;
N−[3−フルオロ−4−(トリフルオロメチル)ベンジル]−N’−(1H−インダゾール−4−イル)尿素;
N−[2−フルオロ−4−(トリフルオロメチル)ベンジル]−N’−(1H−インダゾール−4−イル)尿素;
N−(6−フルオロ−1H−インダゾール−4−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(6−フルオロ−1H−インダゾール−4−イル)−N’−[2−フルオロ−4−(トリフルオロメチル)ベンジル]尿素;
N−(6−フルオロ−1H−インダゾール−4−イル)−N’−[4−(トリフルオロメトキシ)ベンジル]尿素;
N−(5−フルオロ−1H−インダゾール−4−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−[4−(トリフルオロメチル)ベンジル]−N’−[6−(トリフルオロメチル)−1H−インダゾール−4−イル]尿素;
N−[1,2,3]トリアゾロ[1,5−a]ピリジン−7−イル−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−[1,2,3]トリアゾロ[1,5−a]ピリジン−4−イル−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1H−ベンゾイミダゾール−4−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−イミダゾ[1,5−a]ピリジン−5−イル−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1,2−ベンゾイソチアゾール−5−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1H−インダゾール−5−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1−メチル−1H−インダゾール−4−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1−メチル−1H−インダゾール−4−イル)−N’−[4−(トリフルオロメトキシ)ベンジル]尿素;
N−(6−フルオロ−1−メチル−1H−インダゾール−4−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−[1−メチル−6−(トリフルオロメチル)−1H−インダゾール−4−イル]−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(2−メチル−1,3−ベンゾオキサゾール−7−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(2−メチル−1,3−ベンゾオキサゾール−5−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(2−メチル−2H−インダゾール−4−イル)−N’−[4−(トリフルオロメトキシ)ベンジル]尿素;
N−(9H−イミダゾ[1,2−a]インドール−8−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(2−オキソ−2,3−ジヒドロ−1H−インドール−4−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(2,3−ジヒドロ−1−ベンゾフラン−4−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1−メチル−2−オキソ−2,3−ジヒドロ−1H−インドール−4−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(3−メチル−1H−インダゾール−4−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−イミダゾ[1,2−a]ピリジン−5−イル−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1,3−ベンゾチアゾール−7−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(1,2−ベンゾイソチアゾール−7−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(7−アミノ−1,2−ベンゾイソチアゾール−4−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
N−(4−クロロ−1,2−ベンゾイソチアゾール−7−イル)−N’−[4−(トリフルオロメチル)ベンジル]尿素;
並びにそれらの医薬的に許容可能な塩及びN−オキシドから選択される化合物。 - 医薬的に許容可能なキャリヤーと共に請求項1から5のいずれか一項に記載の化合物又は医薬的に許容可能なその塩、N−オキシドもしくはプロドラッグを含有する医薬組成物。
- 治療用としての請求項1から5のいずれか一項に記載の化合物又は医薬的に許容可能なその塩、N−オキシドもしくはプロドラッグ。
- VR1活性を調節することにより改善することが可能な生理的障害の治療又は予防用医薬の製造における請求項1から5のいずれか一項に記載の化合物、又は医薬的に許容可能なその塩、N−オキシドもしくはプロドラッグの使用。
- (A)式(II)の化合物を式(III)の化合物:
(B)式(IV)の化合物を式(V)の化合物:
(C)Xが酸素原子である請求項1に記載の化合物の場合には、式(II)の化合物を式(VI)の化合物:
(D)Xが酸素原子である請求項1に記載の化合物の場合には、式(V)の化合物を式(VII)の化合物:
を含む請求項1に記載の式1の化合物の製造方法。 - VR1活性を調節することにより改善することが可能な生理的障害の治療又は予防方法であって、前記治療又は予防を必要とする患者に有効量の請求項1に記載の式1の化合物、又は医薬的に許容可能なその塩、N−オキシドもしくはプロドラッグを投与することを含む前記方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0322016.7A GB0322016D0 (en) | 2003-09-19 | 2003-09-19 | New compounds |
PCT/GB2004/003968 WO2005028445A2 (en) | 2003-09-19 | 2004-09-16 | Derivatives of n-(1h-indazolyl)- and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for the treatment of pain |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007505877A JP2007505877A (ja) | 2007-03-15 |
JP2007505877A5 true JP2007505877A5 (ja) | 2007-11-08 |
Family
ID=29266326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006526691A Withdrawn JP2007505877A (ja) | 2003-09-19 | 2004-09-16 | 疼痛治療用バニロイド−1受容体(vr1)モジュレーターとしてのn−(1h−インダゾリル)−尿素誘導体及びn−(1h−インドリル)−尿素誘導体並びに関連化合物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070078156A1 (ja) |
EP (1) | EP1675587A2 (ja) |
JP (1) | JP2007505877A (ja) |
CN (1) | CN1856304A (ja) |
AU (1) | AU2004274230A1 (ja) |
CA (1) | CA2538454A1 (ja) |
GB (1) | GB0322016D0 (ja) |
WO (1) | WO2005028445A2 (ja) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
US7417053B2 (en) | 2005-04-07 | 2008-08-26 | Teijin Pharma Limited | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof |
FR2897061B1 (fr) * | 2006-02-03 | 2010-09-03 | Sanofi Aventis | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique. |
TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
FR2903985B1 (fr) * | 2006-07-24 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
FR2904316B1 (fr) | 2006-07-31 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. |
EP2054390B1 (en) | 2006-08-25 | 2012-04-11 | Abbott Laboratories | Indazole derivatives that inhibit trpv1 and uses thereof |
WO2008057300A2 (en) * | 2006-10-27 | 2008-05-15 | Redpoint Bio Corporation | Trpvi antagonists and uses thereof |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
DE102007018149A1 (de) | 2007-04-16 | 2008-10-23 | Grünenthal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
BRPI0810035A2 (pt) * | 2007-04-16 | 2016-07-26 | Gruenenthal Gmbh | ligantes de receptor de vaniloide e seu uso para produção de medicamento |
KR101849560B1 (ko) | 2007-07-12 | 2018-04-17 | 케모센트릭스, 인크. | 염증의 치료를 위한 ccr2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드 |
JP5366269B2 (ja) | 2007-09-14 | 2013-12-11 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 1,3−二置換4−(アリル−x−フェニル)−1h−ピリジン−2−オン |
US9114138B2 (en) | 2007-09-14 | 2015-08-25 | Janssen Pharmaceuticals, Inc. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones |
CN101801930B (zh) | 2007-09-14 | 2013-01-30 | 奥梅-杨森制药有限公司 | 1,3-二取代的-4-苯基-1h-吡啶-2-酮 |
US8785486B2 (en) | 2007-11-14 | 2014-07-22 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
CN102036969A (zh) | 2008-03-20 | 2011-04-27 | 雅培制药有限公司 | 制造作为trpv1拮抗剂的中枢神经系统药剂的方法 |
WO2010025890A1 (en) | 2008-09-02 | 2010-03-11 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
WO2010043396A1 (en) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MX2011011962A (es) | 2009-05-12 | 2012-02-28 | Janssen Pharmaceuticals Inc | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2). |
SG10201402250TA (en) | 2009-05-12 | 2014-07-30 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
JP2013502444A (ja) | 2009-08-24 | 2013-01-24 | アスセピオン ファーマスーティカル、インコーポレイテッド | キナーゼ阻害剤としての5,6−ビシクロヘテロアリール含有尿素化合物 |
EP2377850A1 (en) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
EP2643320B1 (en) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
ES2552879T3 (es) | 2010-11-08 | 2015-12-02 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
WO2012062750A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
US20120115903A1 (en) * | 2010-11-10 | 2012-05-10 | Gruenenthal Gmbh | Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
HUE053734T2 (hu) | 2014-01-21 | 2021-07-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk |
EA201891617A3 (ru) | 2014-01-21 | 2019-04-30 | Янссен Фармацевтика Нв | Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение |
TWI653227B (zh) * | 2014-07-11 | 2019-03-11 | 美商陶氏農業科學公司 | 用於製備4-(1-(4-(全氟乙氧基)苯基)-1h-1,2,4-三唑-3-基)苯甲醯疊氮化物之改良方法 |
GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
KR20190088513A (ko) | 2016-11-23 | 2019-07-26 | 케모센트릭스, 인크. | 국소 분절 사구체경화증의 치료 방법 |
JP2020506895A (ja) | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン2,3−ジオキシゲナーゼおよび/またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
WO2018136887A1 (en) * | 2017-01-23 | 2018-07-26 | Tesaro, Inc. | Compounds |
CN110382500B (zh) * | 2017-03-21 | 2021-08-10 | 正大天晴药业集团股份有限公司 | 用于ido和tdo双重抑制剂的脲类化合物 |
RU2020113612A (ru) | 2017-10-11 | 2021-11-12 | Хемоцентрикс, Инк. | Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2 |
US10696638B2 (en) * | 2017-12-26 | 2020-06-30 | Industrial Technology Research Institute | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same |
US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1182202A (en) * | 1966-03-23 | 1970-02-25 | Ferrania Spa | Photographic Silver Halide Emulsions and Developers containing Indazolone Colour COuplers |
US3647819A (en) * | 1969-09-19 | 1972-03-07 | Sterling Drug Inc | Indazolylphenylureas and indazolyl-phenylthioureas |
US3711610A (en) * | 1971-06-01 | 1973-01-16 | Sterling Drug Inc | Anticoccidiosis method and compositions involving indazolylphenylureas and indazolylphenylthioureas |
US5684041A (en) * | 1996-02-01 | 1997-11-04 | The Procter & Gamble Company | Dihydrobenzofuran and related compounds useful as anti-inflammatory agents |
US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
US7217722B2 (en) * | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
MXPA03001535A (es) * | 2000-08-21 | 2004-12-13 | Pacific Corp | Derivados de tiourea novedosos y las composiciones farmaceuticas que contienen los mismos. |
JP2003192587A (ja) * | 2001-12-26 | 2003-07-09 | Bayer Ag | 尿素誘導体 |
CA2476936A1 (en) * | 2002-02-20 | 2003-08-28 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor |
WO2003087046A1 (en) * | 2002-04-09 | 2003-10-23 | 7Tm Pharma A/S | Novel aminotetraline compounds for use in mch receptor related disorders |
US6933311B2 (en) * | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
-
2003
- 2003-09-19 GB GBGB0322016.7A patent/GB0322016D0/en not_active Ceased
-
2004
- 2004-09-16 EP EP04768514A patent/EP1675587A2/en not_active Withdrawn
- 2004-09-16 US US10/571,544 patent/US20070078156A1/en not_active Abandoned
- 2004-09-16 JP JP2006526691A patent/JP2007505877A/ja not_active Withdrawn
- 2004-09-16 CA CA002538454A patent/CA2538454A1/en not_active Abandoned
- 2004-09-16 AU AU2004274230A patent/AU2004274230A1/en not_active Abandoned
- 2004-09-16 WO PCT/GB2004/003968 patent/WO2005028445A2/en not_active Application Discontinuation
- 2004-09-16 CN CNA2004800271826A patent/CN1856304A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007505877A5 (ja) | ||
JP2010509356A5 (ja) | ||
EA036446B1 (ru) | Соединения и композиции для подавления активности shp2 | |
JP2017537949A5 (ja) | ||
RU2008110917A (ru) | ПРОИЗВОДНЫЕ 7-(2-АМИНО-1-ГИДРОКСИ-ЭТИЛ)-4-ГИДРОКСИБЕНЗОТИАЗОЛ-2(3Н)-ОНА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ | |
JP2012508249A5 (ja) | ||
RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
JP2009504771A5 (ja) | ||
RU2010154172A (ru) | Соединения для лечения рака | |
JP2008526999A5 (ja) | ||
JP2008509187A5 (ja) | ||
JP2011507888A5 (ja) | ||
JP2006501201A5 (ja) | ||
JP2006502143A5 (ja) | ||
RU95118133A (ru) | Гетероциклические соединения, способы их получения и фармацевтическая композиция | |
JP2008524127A5 (ja) | ||
JP2013540114A5 (ja) | ||
JP2011504903A5 (ja) | ||
RU2008105071A (ru) | Соединения и композиции в качестве миметиков tro | |
PE20061156A1 (es) | Derivados de benzamida como agentes inhibidores del transportador de glicina | |
JP2010527984A5 (ja) | ||
JP2010527985A5 (ja) | ||
CA2996681A1 (en) | Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy | |
JP2005517677A5 (ja) | ||
RU2012114718A (ru) | Пиридиновые соединения конденсированного кольца как подтип-селективные модуляторы рецепторов сфингозин-1-фосфата-2 (s1p2) |